This week on the podcast, Dr. Jack Cush recalls what life was like early on during COVID, from March to June of 2020.  During this time, his close friend, Larry, contracted COVID-19 and was hospitalized, intubated and put on mechanical ventilation for nearly 2 months.

EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Psoriatic arthritis (PsA) is plagued by obesity, depression and increased comorbidities; now it appears that polypharmacy adds to the burden of managing PsA.

A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE). 

Researchers have revealed the modulatory effect of the anti-inflammatory metabolite itaconate (ITA) on T helper and T regulatory cells, which may lead to new therapeutic approaches to treating some autoimmune diseases.

An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis).